--- title: "Pre-market hot trades in US stocks: Venus Concept down 7.14% pre-market; Aprea Therapeutics down 5.43% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/274664454.md" description: "Venus Concept pre-market down 7.14%; Aprea Therapeutics pre-market down 5.43%; Fatpipe pre-market up 59.21%; Texxon pre-market up 58.07%; Inlif pre-market up 45.85%" datetime: "2026-02-03T13:27:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274664454.md) - [en](https://longbridge.com/en/news/274664454.md) - [zh-HK](https://longbridge.com/zh-HK/news/274664454.md) --- # Pre-market hot trades in US stocks: Venus Concept down 7.14% pre-market; Aprea Therapeutics down 5.43% pre-market **Hot Pre-Market Trades in US Stocks** Venus Concept is down 7.14% in pre-market trading. Based on recent news, 1. On February 3, Venus Concept Inc. announced through the EDGAR system its financing arrangements secured by the group's real and personal property collateral. This news may have raised market concerns about the company's financial condition, leading to a decline in stock price. 2. On February 3, Venus Concept Inc.'s bridge financing annual interest rate is 12%. High-interest financing may increase the company's financial pressure, further undermining investor confidence and causing the stock price to drop. 3. On February 3, technical sentiment signals indicate a sell. Negative signals from technical indicators may prompt investors to sell shares, leading to a decline in stock price. The medical aesthetics industry has recently faced financing pressures. Aprea Therapeutics is down 5.43% in pre-market trading. Based on recent key news: 1. On February 2, Aprea Therapeutics' Chief Financial Officer John P. Hamill reported the acquisition of the company's common stock. This move may indicate internal confidence in the company's future development, but failed to prevent the stock price from falling. 2. On February 2, Aprea Therapeutics' President and CEO Gilad Oren also reported the acquisition of common stock. This further demonstrates management's optimistic attitude towards the company's prospects, but the market reaction remains negative. 3. On February 2, Recce Pharmaceuticals signed a second R&D agreement with the U.S. Department of Defense to advance research on Recce 327 gel for burn wounds. Although not directly related to Aprea, it shows active dynamics in the biopharmaceutical industry. The biopharmaceutical sector has been active recently, supported by policies. **Top Gainers in Pre-Market Trading in US Stocks** Fatpipe is up 59.21% in pre-market trading. Based on recent key news: 1. On February 3, FatPipe's stock price rose 77.72% in pre-market trading, following a 3.37% increase the previous day. This is mainly due to increased customer demand in the WAN and network security solutions sectors, driving the stock price up. 2. On February 2, the company expanded its sales organization and channel partner network to support its growing business pipeline. Increased recurring billing, customer renewals, and new customer acquisitions have contributed to revenue growth. 3. On February 3, analyst reports indicated that FatPipe's recurring revenue portfolio has significantly strengthened, but analyst ratings have not changed, and the market response is positive. There is growing demand for cybersecurity, and the market reaction is favorable. Texxon is up 58.07% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation Inlif, pre-market up 45.85%, no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation ### Related Stocks - [VERO.US](https://longbridge.com/en/quote/VERO.US.md) - [APRE.US](https://longbridge.com/en/quote/APRE.US.md) ## Related News & Research - [The 'SaaSpocalypse' created the best buying opportunity in cybersecurity in years. Don't miss it.](https://longbridge.com/en/news/282741356.md) - [$1000 Invested In First Trust NASDAQ Cybersecurity ETF 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/282720743.md) - [ZAWYA: Cybersecurity dominates the leadership agenda in the Middle East as AI readiness lags](https://longbridge.com/en/news/282657790.md) - [Wall Street Is Wrong About AI Killing Software Stocks. This Cybersecurity Growth Stock Proves It.](https://longbridge.com/en/news/282596406.md) - [A Look At Palo Alto Networks (PANW) Valuation After Project Glasswing AI Cybersecurity Partnership](https://longbridge.com/en/news/282456886.md)